Compound Therapeutics Appoints Dr. John Mendlein As CEO; Biotech Executive to Accelerate Partnering and Development of a Breakthrough Class of Pharmaceuticals.

WALTHAM, Mass. -- Compound Therapeutics announced today that Dr. John Mendlein has been appointed chief executive officer to accelerate the development of the Company's oncology product pipeline based on a new, proprietary class of pharmaceuticals, AdNectins. Dr. Mendlein has over 20 years of experience in the pharmaceutical industry, including biotechnology and top tier pharmaceutical companies.

Compound Therapeutics' founding CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Dr. Frank Lee, will continue at the Company as chairman of the board, and Dr. L. Patrick Gage, former executive chairman, transitions to non-executive director.

"John's commercial and drug development expertise are ideally suited to the next stage of growth for our pipeline and product engine," commented Dr. Frank Lee, chairman of Compound Therapeutics' Board of Directors. "His scientific, legal, and business experience from public and private companies will be key as we advance our first product into the clinic and initiate corporate alliances."

"Compound Therapeutics has tremendous potential to build a commercially valuable pipeline based on a novel class of protein therapeutics," noted Dr. John Mendlein, Compound Therapeutics' chief executive officer. "Under Frank's leadership the company has rapidly advanced an important oncology product on a key pathway that demonstrates the development speed and power of this class of proteins and product engine. We look forward to the clinical data for this new class as we lead protein therapeutics beyond naturally occurring proteins and antibodies."

Prior to joining Compound, Dr. Mendlein was chairman and CEO of Affinium Pharmaceuticals, a privately held company privately held company

A firm whose shares are held within a relatively small circle of owners and are not traded publicly. developing novel anti-infectives, where he remains chairman. He was also chief knowledge officer and general counsel at Aurora Bioscience Corporation (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ABSC) and an attorney in the Technology Litigation Group at Cooley Godward LLP.

Dr. Mendlein serves on numerous boards, including ViroLogic and the Emerging Companies Section of the Biotechnology Industry Organization Biotechnology Industry Organization or BIO was founded 1993 in Washington, DC. James C. Greenwood is BIO's current President. External links

BIO Website

(BIO). Dr. Mendlein holds a J.D. from the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). , Hastings College of Law; a Ph.D. in Physiology and Biophysics biophysics, application of various methods and principles of physical science to the study of biological problems. In physiological biophysics physical mechanisms have been used to explain such biological processes as the transmission of nerve impulses, the muscle from the University of California, Los Angeles UCLA comprises the College of Letters and Science (the primary undergraduate college), seven professional schools, and five professional Health Science schools. Since 2001, UCLA has enrolled over 33,000 total students, and that number is steadily rising. ; and a B.S. in Biology from the University of Miami This article is about the university in Coral Gables, Florida. For the university in Oxford, Ohio, see Miami University.

The University of Miami (also known as Miami of Florida,^[2] UM,^[3] or just The U .

About Compound Therapeutics

Compound Therapeutics is advancing new classes of targeted protein therapeutics by leveraging its innovative, proprietary product engine. AdNectins are small binding proteins that have clinical and commercial advantages over antibodies and other therapeutic proteins, including use against a wide range of biological targets, rapid development time, and cost-effective production. AdZymes are a new class of high potency, high-specificity protein antagonists that combine targeting domains with enzymes. Compound's initial pipeline is in oncology with the lead product in late preclinical development. The company is funded by three leading venture capital firms Name Location Founding date Managing Partners/Directors Specialty Capital managed
5AM Ventures Menlo Park, CA; Waltham, MA 2002 John Diekman, PhD (managing partner), Scott Rocklage, PhD (managing partner), Andrew Schwab (managing partner) life sciences $200M ^[1] : Atlas Venture, Flagship Ventures, and Polaris Venture Partners.

For more information, please visit www.compoundtherapeutics.com.

COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Publication:	Business Wire
Date:	Jun 15, 2005
Words:	442
Previous Article:	ARAMARK Named Among the 30 Best Companies for Diversity by Black Enterprise Magazine.
Next Article:	EB Games Celebrates Opening of Its New Store Location in Oak Park Heights, MN.

Related Articles
MPM CAPITAL LEADS EUR22 MILLION FINANCING OF BIOXELL.
Richard S. Kent, M.D. Named President and CEO of Serenex, Inc.
Cengent Therapeutics Signs Genes-To-Leads Drug Discovery Contract with Dynamis Therapeutics.
Compound Therapeutics Announces Initiation of IND-enabling Safety Studies with Lead Oncology Product; First of a New Class of Protein Therapeutics.
Adnexus Therapeutics Closes $27M Series B Funding; Series B Financing Led by Venrock will Advance Breakthrough New Product Class, AdNectins.
Medior Announces Completion of Series A Financing Round and Appointment of CEO and Chairman.
Adnexus Therapeutics Expands and Strengthens Senior Management Team; Experienced Drug Development Team to Drive Adnectin Product Pipeline and...
Adnexus Therapeutics Appoints L. Patrick Gage, Ph.D., as Chairman of the Board of Directors.
Adnexus Therapeutics to Present at UBS Global Life Sciences Conference on Tuesday, September 26.
BIOLINERX LICENSES PEPTIDE FOR INFLAMMATORY DISEASES.